BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019
December 13, 2019 07:00 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Dec. 13, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical Data on BRUKINSA™ (Zanubrutinib) at the 61st American Society of Hematology (ASH) Annual Meeting
December 08, 2019 16:45 ET | BeiGene, LTD.
Oral presentations on data from two clinical trials in chronic lymphocytic leukemia or small lymphocytic lymphoma Poster presentation on data from clinical trial of BRUKINSA combined with...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Reports Third Quarter 2019 Financial Results
November 12, 2019 16:05 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Nov. 12, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 61st American Society of Hematology Annual Meeting
November 06, 2019 09:00 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Nov. 06, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Global Strategic Oncology Collaboration with Amgen
October 31, 2019 16:00 ET | BeiGene, LTD.
• Companies to Collaborate on the Commercialization of XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) in China  • Companies to Jointly Develop 20 Amgen Oncology Pipeline...
hagens.jpg
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud: Investors Who Suffered Losses Encouraged to Contact Firm
October 29, 2019 20:02 ET | Hagens Berman Sobol Shapiro LLP
Class-action law firm urges BGNE investors who have suffered significant losses to submit your loss now to learn if they qualify to recover their investment losses. SAN FRANCISCO, Oct. 29, 2019 ...
HAGENS-BERMAN-securities-press-release.jpg
BGNE INVESTOR REMINDER: Hagens Berman Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud
October 07, 2019 20:05 ET | Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Hagens Berman reminds BGNE investors that it has launched an investigation into BeiGene, Ltd. (NASDAQ: BGNE) regarding possible violations of Federal...
HAGENS-BERMAN-securities-press-release.jpg
BGNE INVESTOR REMINDER: Hagens Berman Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud
September 30, 2019 20:04 ET | Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Hagens Berman reminds BGNE investors that it has launched an investigation into BeiGene, Ltd. (NASDAQ: BGNE) regarding possible violations of...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical Data on Tislelizumab and Pamiparib Presented at the European Society for Medical Oncology (ESMO) Congress 2019
September 30, 2019 06:00 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical Data on Tislelizumab and Pamiparib to Be Presented at the European Society for Medical Oncology (ESMO) Congress 2019
September 26, 2019 18:05 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 26, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...